November 18, 2021
Life Sciences
  • AstraZeneca released new clinical trial results showing that its antibody treatment is highly effective at preventing COVID-19 in people who may not respond well to vaccines. According to the trial, patients given a single injection of the treatment were 83 percent less likely to develop symptomatic cases of the virus than participants who were given a placebo. Furthermore, six months after treatment was administered, no severe cases of COVID-19 or death were reported among the group. In a group given the placebo, five participants contracted severe COVID-19 within six months of the trial beginning, and there were two COVID-19-related deaths. (Articles here and here)